HIV and multidrug-resistant tuberculosis: Overlapping epidemics

European Respiratory Journal

Volumn 44, Issue 1, 2014, Pages 251-254

  Dean, Anna S ^a   Zignol, Matteo ^a   Falzon, Dennis ^a   Getahun, Haileyesus ^a   Floyd, Katherine ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

AWARENESS; DISEASE PREDISPOSITION; DRUG SENSITIVITY; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LETTER; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; COMORBIDITY; COMPLICATION; FACTUAL DATABASE; HEALTH; HIV INFECTIONS; INFECTION CONTROL; INFECTIOUS DISEASE MEDICINE; INFORMATION PROCESSING; INTERNATIONAL COOPERATION; PROCEDURES; STATISTICAL ANALYSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

COMMUNICABLE DISEASE CONTROL; COMORBIDITY; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; EPIDEMICS; GLOBAL HEALTH; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INFECTIOUS DISEASE MEDICINE; INTERNATIONAL COOPERATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84903842829     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00205413     Document Type: Letter

References (15)

1. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-550.
2. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
3. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
4. World Health Organization. Global Tuberculosis Report 2013. www.who.int/tb/publications/global-report/en/index.htmlDatelastaccessed: November1,2013.Datelastupdated:2013.
5. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276: 1229-1235.
6. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. 4th Edn. http://whqlibdoc.who.int/publications/2009/ 9789241598675-eng.pdfDatelastaccessed:August6,2013.Datelastupdated:2009.
7. Mesfin YM, Hailemariam D, Biadglign S, et al. Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis. PLoS ONE 2014; 9: e82235.
8. Suchindran S, Brouwer ES, Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis. A systematic review. PLoS ONE 2009; 4: e5561.
9. Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196: Suppl. 1, S86-S107.
10. Jenkins HE, Plesca V, Ciobanu A, et al. Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a highburden country. Eur Respir J 2012; 42: 1291-1301.
11. Moonan PK, Teeter LD, Salcedo K, et al. Transmission of multidrug-resistant tuberculosis in the USA: a crosssectional study. Lancet Infect Dis 2013; 13: 777-784.
12. Porco TC, Oh P, Flood JM. Antituberculosis drug resistance acquired during treatment: an analysis of cases reported in California, 1994-2006. Clin Infect Dis 2013; 56: 761-769.
13. Falzon D, Jaramillo E, Wares F, et al. Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis 2013; 13: 690-697.
14. Nardell E, Dharmadhikari A. Turning off the spigot: reducing drug-resistant tuberculosis transmission in resourcelimited settings. Int J Tuberc Lung Dis 2010; 14: 1233-1243.
15. Getahun H, Gunneberg C, Granich R, et al. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 2010; 50: S201-S207.